Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 19 - 120 |
| Updated: | 1/26/2018 |
| Start Date: | May 2002 |
| End Date: | March 2015 |
A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different
ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and
combination chemotherapy with autologous stem cell transplantation may allow the doctor to
give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination
chemotherapy followed by autologous hematopoietic stem cell transplantation in treating
patients who have B-cell non-Hodgkin's lymphoma.
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different
ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and
combination chemotherapy with autologous stem cell transplantation may allow the doctor to
give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination
chemotherapy followed by autologous hematopoietic stem cell transplantation in treating
patients who have B-cell non-Hodgkin's lymphoma.
OBJECTIVES:
- Determine the levels of soluble CD20 antigen (sCD20) in the blood before and after
treatment with rituximab and carmustine, cytarabine, etoposide, and melphalan followed
by autologous hematopoietic stem cell transplantation in patients with CD20-positive
B-cell non-Hodgkin's lymphoma.
- Correlate the effect of changes in levels of sCD20 with clinical outcomes in patients
treated with this regimen.
- Determine the response rate in patients treated with this regimen.
- Determine the event-free survival of patients treated with this regimen.
- Determine the toxicity profile of this regimen in these patients.
OUTLINE: Patients receive rituximab IV over approximately 3-4 hours once weekly for 2 weeks
followed 1 week later by hematopoietic stem cell or bone marrow harvest.
Patients then receive a third dose of rituximab IV over approximately 3-4 hours on day -7 or
-6. Patients also receive high-dose chemotherapy comprising carmustine IV on day -6,
cytarabine IV and etoposide IV twice daily on days -5 to -2, and melphalan IV on day -1.
Patients undergo autologous hematopoietic stem cell transplantation on day 0.
Patients who have less than a complete remission at day 100 post-transplantation receive 4
additional doses of rituximab IV over approximately 3-4 hours once weekly for 4 weeks.
Patients are followed at day 100, at 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
- Determine the levels of soluble CD20 antigen (sCD20) in the blood before and after
treatment with rituximab and carmustine, cytarabine, etoposide, and melphalan followed
by autologous hematopoietic stem cell transplantation in patients with CD20-positive
B-cell non-Hodgkin's lymphoma.
- Correlate the effect of changes in levels of sCD20 with clinical outcomes in patients
treated with this regimen.
- Determine the response rate in patients treated with this regimen.
- Determine the event-free survival of patients treated with this regimen.
- Determine the toxicity profile of this regimen in these patients.
OUTLINE: Patients receive rituximab IV over approximately 3-4 hours once weekly for 2 weeks
followed 1 week later by hematopoietic stem cell or bone marrow harvest.
Patients then receive a third dose of rituximab IV over approximately 3-4 hours on day -7 or
-6. Patients also receive high-dose chemotherapy comprising carmustine IV on day -6,
cytarabine IV and etoposide IV twice daily on days -5 to -2, and melphalan IV on day -1.
Patients undergo autologous hematopoietic stem cell transplantation on day 0.
Patients who have less than a complete remission at day 100 post-transplantation receive 4
additional doses of rituximab IV over approximately 3-4 hours once weekly for 4 weeks.
Patients are followed at day 100, at 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Diagnosis of non-Hodgkin's lymphoma
- Any B cell
- CD20-positive disease
- Failed prior primary induction therapy
- Meets 1 of the following criteria:
- Chemotherapy-refractory disease
- Received at least 3 prior chemotherapy regimens
- Mantle cell lymphoma
- Eligible for transplantation
- No history of T-cell lymphoma
PATIENT CHARACTERISTICS:
Age
- 19 and over
Performance status
- WHO 0-2
Life expectancy
- At least 6 months
Hematopoietic
- Absolute neutrophil count ≥ 1,000/mm^3*
- Platelet count > 50,000/mm^3*
- Hemoglobin > 9.0 g/dL* NOTE: *Unless due to lymphomatous involvement of the bone
marrow
Hepatic
- Not specified
Renal
- Not specified
Other
- Not pregnant or nursing
- Fertile patients must use 2 methods of effective contraception
- No other concurrent serious disease or condition that would preclude study
participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
We found this trial at
1
site
985950 Nebraska Medical Center
Omaha, Nebraska 68198
Omaha, Nebraska 68198
402-559-4090
UNMC Eppley Cancer Center at the University of Nebraska Medical Center The Fred & Pamela...
Click here to add this to my saved trials
